STOCK TITAN

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Sangamo Therapeutics (SGMO) has scheduled its fourth quarter and full year 2024 financial results release for Monday, March 17, 2025, after market close. The company will host an earnings conference call at 4:30 p.m. Eastern on the same day.

Additionally, Sangamo announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida, from March 11-13, 2025. CEO Sandy Macrae will present on Wednesday, March 12 at 12:00 p.m. Eastern. Both the earnings call and conference presentation will be accessible via webcast, with replays available afterward.

Sangamo Therapeutics (SGMO) ha programmato la pubblicazione dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per lunedì 17 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conference call sugli utili alle 16:30 ora orientale nello stesso giorno.

Inoltre, Sangamo ha annunciato la sua partecipazione alla 27ª Conferenza Annuale Mondiale sulla Salute di Barclays a Miami, Florida, dal 11 al 13 marzo 2025. Il CEO Sandy Macrae presenterà mercoledì 12 marzo alle 12:00 ora orientale. Sia la chiamata sugli utili che la presentazione alla conferenza saranno accessibili tramite webcast, con repliche disponibili successivamente.

Sangamo Therapeutics (SGMO) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el lunes 17 de marzo de 2025, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica sobre ganancias a las 4:30 p.m. hora del Este ese mismo día.

Además, Sangamo anunció su participación en la 27ª Conferencia Anual Global de Salud de Barclays en Miami, Florida, del 11 al 13 de marzo de 2025. El CEO Sandy Macrae presentará el miércoles 12 de marzo a las 12:00 p.m. hora del Este. Tanto la llamada de ganancias como la presentación de la conferencia estarán disponibles a través de webcast, con repeticiones disponibles posteriormente.

상가모 테라퓨틱스 (SGMO)는 2025년 3월 17일 월요일, 시장 마감 후 2024년 4분기 및 전체 연도 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 동부 표준시로 오후 4시 30분에 실적 컨퍼런스 콜을 개최합니다.

또한, 상가모는 2025년 3월 11일부터 13일까지 플로리다 마이애미에서 열리는 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 샌디 맥크래이는 3월 12일 수요일 동부 표준시로 오후 12시에 발표할 예정입니다. 실적 전화와 컨퍼런스 발표 모두 웹캐스트를 통해 접근 가능하며, 이후 재생도 가능합니다.

Sangamo Therapeutics (SGMO) a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le lundi 17 mars 2025, après la clôture du marché. L'entreprise organisera une conférence téléphonique sur les résultats à 16h30, heure de l'Est, le même jour.

De plus, Sangamo a annoncé sa participation à la 27ème Conférence Annuelle Mondiale sur la Santé de Barclays à Miami, en Floride, du 11 au 13 mars 2025. Le PDG Sandy Macrae présentera le mercredi 12 mars à 12h00, heure de l'Est. La conférence téléphonique sur les résultats et la présentation de la conférence seront accessibles par webdiffusion, avec des rediffusions disponibles par la suite.

Sangamo Therapeutics (SGMO) hat die Veröffentlichung der finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Montag, den 17. März 2025, nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern eine Gewinnkonferenzschaltung abhalten.

Zusätzlich gab Sangamo seine Teilnahme an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami, Florida, vom 11. bis 13. März 2025 bekannt. CEO Sandy Macrae wird am Mittwoch, den 12. März um 12:00 Uhr Eastern präsentieren. Sowohl der Gewinnanruf als auch die Konferenzpräsentation werden über Webcast zugänglich sein, mit späteren Wiederholungen.

Positive
  • None.
Negative
  • None.

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference.

Fourth Quarter and Full Year 2024 Earnings Results

The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

A replay will be available following the conference call, accessible under Events.

Upcoming Investor Conference Participation

Sangamo will participate in the Barclays 27th Annual Global Healthcare Conference, to be held from March 11-13, 2025, in Miami, Florida.

Sandy Macrae, Sangamo’s President and Chief Executive Officer is scheduled to present on Wednesday, March 12 at 12:00 p.m. Eastern. A live webcast of the presentation will be available here and on the Sangamo Therapeutics website in the Investors and Media section under Events. A replay of the presentation will be available for 90 days following the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.

Investor Relations & Media Inquiries

Louise Wilkie

ir@sangamo.com

media@sangamo.com

Source: Sangamo Therapeutics, Inc.

FAQ

When will Sangamo Therapeutics (SGMO) release its Q4 and full year 2024 earnings?

Sangamo will release its Q4 and full year 2024 earnings after market close on Monday, March 17, 2025.

What time is Sangamo's (SGMO) Q4 2024 earnings conference call?

The earnings conference call is scheduled for 4:30 p.m. Eastern on Monday, March 17, 2025.

When is Sangamo (SGMO) presenting at the Barclays Healthcare Conference?

CEO Sandy Macrae will present at the Barclays Conference on Wednesday, March 12, 2025, at 12:00 p.m. Eastern.

Where can investors access Sangamo's (SGMO) Q4 2024 earnings call?

Investors can access the call through a registration link provided by the company, with options for dial-in or dial-out connections.
Sangamo Therapeutics Inc

NASDAQ:SGMO

SGMO Rankings

SGMO Latest News

SGMO Stock Data

198.63M
203.06M
2.38%
24.5%
10.76%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RICHMOND